Introduction
Aspirin is widely recognized as a potent chemopreventive agent, particularly in reducing the incidence and mortality of colorectal cancer (CRC). However, clinical outcomes have been notoriously inconsistent across different patient populations. While the gut microbiota is known to be a pivotal regulator in CRC development and a significant player in drug metabolism, its specific role in aspirin-mediated prevention has remained unclear. This study investigates whether the gut microbiome acts as a metabolic barrier, deactivating aspirin before it can exert its protective effects.
Methodology
To decipher the relationship between the microbiome and aspirin efficacy, researchers utilized two distinct mouse models of colorectal cancer: the azoxymethane/dextran sulfate sodium (AOM/DSS) chemically induced model and the $APC^{min/+}$ genetic model.
The study compared three groups of mice:
- Microbiota-intact mice: Conventionally reared mice with a standard gut microbiome.
- Microbiota-depleted mice: Mice treated with a broad-spectrum antibiotic cocktail (vancomycin, ampicillin, metronidazole, and neomycin).
- Germ-free (GF) mice: Mice raised in a sterile environment, lacking any microbiota.
Aspirin was administered orally (400 mg/L). The researchers used Ultra-High Performance Liquid Chromatography (UHPLC) to measure aspirin concentrations in plasma and culture media. To identify specific aspirin-degrading bacteria, they screened 1,093 bacterial colonies isolated from mouse feces using 16S rRNA gene sequencing and validated findings through monocolonization experiments in germ-free mice.
Key Findings
The Microbiome Impairs Aspirin Efficacy
The most significant finding was that aspirin’s ability to reduce tumor load was contingent on the state of the gut microbiota. In both the AOM/DSS and $APC^{min/+}$ models, aspirin significantly reduced tumor number and load in antibiotic-treated and germ-free mice. Conversely, in mice with an intact microbiome, aspirin treatment failed to produce a significant reduction in tumor metrics. This suggests that the presence of certain gut bacteria actively interferes with aspirin’s chemopreventive function.
Impact on Systemic Bioavailability
UHPLC analysis revealed the mechanism behind this interference: bioavailability. Plasma levels of aspirin were significantly higher in microbiota-depleted and germ-free mice compared to those with intact microbiomes. Furthermore, when aspirin was co-incubated with fecal commensal bacteria from microbiota-intact mice, the drug levels in the medium were rapidly reduced. This confirmed that the gut microbiota limits the amount of aspirin that reaches the bloodstream by degrading it within the gastrointestinal tract.
Identification of Lysinibacillus sphaericus
Through systematic screening of over a thousand bacterial isolates, the researchers identified Lysinibacillus sphaericus as a primary culprit. This specific bacterium was shown to significantly reduce aspirin levels in vitro. To confirm its role in vivo, germ-free mice were monocolonized with L. sphaericus. These mice exhibited significantly lower plasma aspirin levels following oral administration compared to sterile germ-free mice, proving that this single species is sufficient to reduce aspirin bioavailability.
Discussion and Implications
This research highlights a critical, previously overlooked factor in cancer prevention: the microbial metabolism of drugs. The discovery that L. sphaericus (and potentially other species) can degrade aspirin suggests that a "one-size-fits-all" approach to aspirin dosing for CRC prevention may be ineffective.
Precision Prevention
The study opens the door for "precision chemoprevention," where a patient’s gut microbiome profile could be screened before starting an aspirin regimen. If aspirin-degrading bacteria are present, clinicians might consider:
- Adjusting the aspirin dosage.
- Using antibiotics or probiotics to modulate the microbiome.
- Developing inhibitors to target specific bacterial enzymes responsible for degradation.
Conclusion
The gut microbiota significantly modulates the chemopreventive efficacy of aspirin in mice by reducing its systemic bioavailability. Lysinibacillus sphaericus plays a critical role in this process through aspirin degradation. Future research is needed to translate these findings into human clinical practice, potentially leading to more effective, personalized strategies for colorectal cancer prevention.
Summary updated